Tempest Therapeutics Inc (TPST)

Mar 27, 2025, 4:10 PM EDT - 7 days ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 25, 2025, 4:30 PM EDT - 9 days ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 13, 2025, 8:00 AM EDT - 21 days ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Feb 10, 2025, 8:00 AM EST - 7 weeks ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 7, 2025, 4:30 PM EST - 7 weeks ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2025, 8:00 AM EST - 3 months ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Nov 25, 2024, 4:30 PM EST - 4 months ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 4:21 PM EST - 5 months ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 10, 2024, 9:06 AM EDT - 6 months ago

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Oct 10, 2024, 7:01 AM EDT - 6 months ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Sep 20, 2024, 4:30 PM EDT - 6 months ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2024, 8:00 AM EDT - 7 months ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 8:00 AM EDT - 8 months ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 8, 2024, 4:56 PM EDT - 8 months ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 20, 2024, 9:43 AM EDT - 10 months ago

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Jun 18, 2024, 6:22 PM EDT - 10 months ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

May 31, 2024, 3:45 PM EDT - 10 months ago

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 9, 2024, 4:29 PM EDT - 11 months ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 17, 2024, 1:26 PM EDT - 1 year ago

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Mar 19, 2024, 4:25 PM EDT - 1 year ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 5, 2024, 4:30 PM EST - 1 year ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Nov 20, 2023, 8:00 AM EST - 1 year ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 8, 2023, 5:17 PM EST - 1 year ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 13, 2023, 4:13 PM EDT - 1 year ago

Tempest Therapeutics shares end wild week with 8% drop

Oct 12, 2023, 12:49 PM EDT - 1 year ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 11:26 AM EDT - 1 year ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Oct 11, 2023, 12:29 PM EDT - 1 year ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 8:01 AM EDT - 1 year ago

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:00 AM EDT - 1 year ago

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Oct 10, 2023, 4:05 PM EDT - 1 year ago

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Aug 10, 2023, 4:13 PM EDT - 1 year ago

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

May 31, 2023, 4:05 PM EDT - 2 years ago

Tempest to Present at the Jefferies Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

May 10, 2023, 4:15 PM EDT - 2 years ago

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 27, 2023, 4:58 PM EDT - 2 years ago

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Apr 26, 2023, 6:41 PM EDT - 2 years ago

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Mar 22, 2023, 5:26 PM EDT - 2 years ago

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Mar 14, 2023, 4:30 PM EDT - 2 years ago

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

Nov 22, 2022, 4:05 PM EST - 2 years ago

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 8, 2022, 8:00 AM EST - 2 years ago

Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 6, 2022, 8:00 AM EDT - 2 years ago

Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit

Aug 15, 2022, 8:00 AM EDT - 2 years ago

Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update

Jul 7, 2022, 8:00 AM EDT - 2 years ago

Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference

Jun 6, 2022, 4:05 PM EDT - 3 years ago

Tempest to Present at the Jefferies Healthcare Conference

May 26, 2022, 4:57 PM EDT - 3 years ago

Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting

May 13, 2022, 8:00 AM EDT - 3 years ago

Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights

Apr 27, 2022, 12:09 PM EDT - 3 years ago

Why Tempest Therapeutics Shares Are Rising